Skip to main content

Table 2 List of patients with clinical, immunohistochemical and FISH data

From: OLIG2 is a novel immunohistochemical marker associated with the presence of PAX3/7-FOXO1 translocation in rhabdomyosarcomas

ID

Sex

Age yrs

Histo-logy

Stage

Meta-stases

TFAP2B IHC

ALK IHC

OLIG2 IHC

FISH PAX3/7-FOXO1 fusion

1

F

2

ARMS

IV

M1

+

+

+/−

inconclusive, FOXO1 amp.

2

M

15

ARMS

IV

M1

+

+

PAX3-FOXO1

3

M

14

ARMS

II

M0

+

+

+

PAX3-FOXO1

4

M

3.5

ARMS

II

M0

+

+

+

PAX3-FOXO1

5

M

1.5

ARMS

II

M1

+

+

+

inconclusive

6

M

8

ARMS

IV

M1

+

+

+

PAX7-FOXO1 and amp.

7

F

3

ARMS

IV

M1

+

+

+

PAX3-FOXO1

8

M

< 1

ARMS

IV

M1

negative

9

M

17

ARMS

IV

M1

negative

10

F

10

ARMS

IV

M1

+/−

negative

11

F

< 1

ARMS

II

M1

+/−

negative

12

M

4.5

ERMS

II

M0

+

+

+

PAX3-FOXO1

13

F

7.5

ERMS

III

M0

+

+

+

PAX3-FOXO1

14

M

12

ERMS

III

M1

+

PAX3-FOXO1

15

F

1.5

ERMS1

na

na

+

+/−

negative

16

F

4

ERMS

III

M0

+

negative

17

M

16

ERMS

II

M0

negative

18

M

8

ERMS

IV

M1

negative

19

M

14

ERMS

IV

M1

negative

20

M

9

ERMS

III

M0

negative

21

M

4

ERMS

I

M0

negative

22

F

5

ERMS

III

M1

negative

23

F

< 1

ERMS

II

na

negative

24

M

7

ERMS

I

M0

negative

25

M

7

ERMS

II

M0

negative

26

F

5

ERMS

I

M0

negative

27

M

< 1

ERMS

I

M0

+/−

inconclusive

28

F

1

ERMS

IV

M1

+/−

negative

29

M

2

ERMS

III

M1

+

negative

30

M

17

ERMS

III

M0

nd

31

M

< 1

ERMS

III

M0

nd

32

F

4.5

ERMS

IV

M1

nd

33

M

< 1

ERMS

I

M0

nd

34

M

3

ERMS

III

M0

nd

35

M

7

ERMS

III

M0

nd

36

M

3

ERMS

II

M0

nd

37

F

6

ERMS

III

M0

nd

38

M

10

ERMS

III

na

nd

39

M

11

ERMS

I

M0

nd

40

M

1

ERMS

I

M0

nd

41

M

11

ERMS

IV

M1

nd

42

F

7

ERMS

IV

M1

nd

43

F

15

ERMS

III

M0

nd

44

M

3

ERMS

II

M0

nd

45

F

1

ERMS

na

na

nd

  1. ARMS Alveolar rhabdomyosarcoma; ERMS embryonal rhabdomyosarcoma
  2. ERMS1 ERMS with alveolar variant elements
  3. M0 No distant metastases; M1 Distant metastases present; IHC immunohistochemistry; +/−intermediate reaction present in 10–50% of cells; FISH Fluorescence in situ hybridization; AMP Amplification; nd Not done; na Not available